Slingshot members are tracking this event:

MedImmune, a research and development arm of AstraZeneca (AZN), agrees to partner with Sanofi (SNY) to develop anti-respiratory syncytial virus (RSV) prevention treatment MEDI8897

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AZN Community voting in process
SNY Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 03, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Medimmune, Anti-resperatory Syncytial Virus, Rsv, Medi8897